Heritage Cannabis Holdings said that its subsidiary CannaCure Corp. has entered into a three-year extraction and finished product supply agreement with Brazil-based Entourage Participacoes S.A. or Entourage Phytolab for the distribution of pharmaceutical products in Brazil.
Heritage is a Canada-based cannabis company focused on the production and sale of medical as well as recreational hemp-based and cannabis-based products.
Entourage Phytolab is a biotech company engaged in the research and development of cannabis-based medicine. The company's first products are scheduled to hit the market this year and will be used to treat problems such as epilepsy, chronic pain, cancer pain, insomnia, and arthritis.
Under the terms of the deal, Heritage will supply hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels as well as cannabis-derived THC dominant 2.5 and 5.0 mg softgels to Entourage Phytolab.
As part of the long-term agreement, CannaCure will provide cannabis and hemp products to be used strictly for pharmaceutical products that comply with regulations issued by the Brazil Health Authority, Anvisa.
These include GMP certification and GMP compliant products. CannaCure is currently in the process of obtaining GMP certification.
CannaCure will supply initial products for Entourage Phytolab's formulation as well as research and development purposes by February 2021. The company will deliver commercial orders after it receives EU GMP certification, which is estimated to be in the latter half of 2021.
CannaCure and Entourage Phytolab have established minimum order quantities mutually agreed to by both companies.
In December, Heritage Cannabis said it entered into an agreement with CannaBR Exports Corp., a Brazilian focused pharmaceutical CBD product importation and distribution company, for the distribution and sale of bulk CBD products to the Brazilian cannabis market.
For comments and feedback contact: editorial@rttnews.com
Business News